GLUE Stock Price, Monte Rosa Therapeutics, . Quote, Chart

Market Summary

USD5.18-0.04

Delayed

-0.77%

GLUE Stock Price

View Fullscreen

GLUE RSI Chart

GLUE Valuation

Market Cap

261.7M

Price/Earnings (Trailing)

-1.93

EV/EBITDA

-1.22

Price/Free Cashflow

-3.75

MarketCap/EBT

-1.94

GLUE Price/Earnings (Trailing)

GLUE Profitability

Return on Equity

-88.7%

Return on Assets

-50.72%

Free Cashflow Yield

-26.68%

GLUE Fundamentals

GLUE Earnings

Earnings (TTM)

-135.3M

Earnings Growth (Yr)

0.22%

Earnings Growth (Qtr)

3.86%

Breaking Down GLUE Revenue

Last 7 days

6.8%

Last 30 days

-10.7%

Last 90 days

-13.1%

Trailing 12 Months

-6.5%

How does GLUE drawdown profile look like?

GLUE Financial Health

Current Ratio

4.82

GLUE Investor Care

Shares Dilution (1Y)

2.28%

Tracking the Latest Insider Buys and Sells of Monte Rosa Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 28, 2021	versant venture capital vi, l.p.	acquired	-	-	6,515,870	-
Jun 28, 2021	cormorant asset management, lp	acquired	-	-	2,602,200	-
Jun 28, 2021	behbahani ali	acquired	-	-	6,642,300	-
Jun 28, 2021	behbahani ali	bought	19,950,000	19.00	1,050,000	-
Jun 28, 2021	landsman liza	acquired	-	-	6,642,300	-
Jun 28, 2021	landsman liza	bought	19,950,000	19.00	1,050,000	-
Jun 28, 2021	makhzoumi mohamad	acquired	-	-	6,642,300	-
Jun 28, 2021	makhzoumi mohamad	bought	19,950,000	19.00	1,050,000	-
Jun 28, 2021	versant venture capital vi, l.p.	acquired	-	-	1,940,040	-
Jun 28, 2021	cormorant asset management, lp	bought	11,400,000	19.00	600,000	-

Which funds bought or sold GLUE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	1,177	5,929	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-68.66	-243,291	156,249	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.03	-6,430	21,933	-%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	new	-	850,561	850,561	-%
May 15, 2024	UBS OCONNOR LLC	sold off	-100	-249,996	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	420	2,115	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	6,882,530	34,658,500	0.44%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	122	677,550	1,057,680	-%
May 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	sold off	-100	-274,087	-	-%
May 15, 2024	NEA Management Company, LLC	unchanged	-	10,769,200	54,230,700	3.37%

Are Funds Buying or Selling GLUE?

Are funds buying GLUE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GLUE

No. of Funds

Unveiling Monte Rosa Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	new enterprise associates 17, l.p.	15.2%	7,692,298	SC 13D/A
Apr 10, 2024	price t rowe associates inc /md/	10.2%	5,096,787	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	9.9%	4,941,707	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.1%	4,535,000	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	blackrock inc.	4.7%	2,371,980	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	9.8%	4,916,095	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Nov 09, 2023	versant venture capital vi, l.p.	13.7%	6,799,115	SC 13D/A
Feb 14, 2023	avoro capital advisors llc	8.9%	4,325,000	SC 13G/A

Recent SEC filings of Monte Rosa Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	424B5	Prospectus Filed
May 16, 2024	8-K	Current Report
May 15, 2024	424B5	Prospectus Filed
May 13, 2024	SC 13D/A	13D - Major Acquisition
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
May 01, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	ARS	ARS

Peers (Alternatives to Monte Rosa Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Monte Rosa Therapeutics, Inc. News

Latest updates

Monte Rosa Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-12.2%	267	304	252	279	309	342	358	365	346	366	384	369	49.00
Current Assets	-15.7%	199	236	183	208	241	276	295	297	320	349	371	358	44.00
Cash Equivalents	-18.3%	105	128	59.00	47.00	52.00	55.00	112	104	138	351	367	357	43.00
Net PPE	0.7%	34.00	34.00	35.00	35.00	33.00	27.00	19.00	15.00	13.00	12.00	12.00	9.00	5.00
Liabilities	-8.3%	114	125	68.00	65.00	65.00	71.00	67.00	63.00	20.00	19.00	15.00	12.00	30.00
Current Liabilities	-11.4%	41.00	47.00	23.00	19.00	21.00	26.00	22.00	15.00	12.00	17.00	13.00	11.00	29.00
Shareholder's Equity	-14.9%	153	179	185	214	244	271	291	302	326	348	369	357	49.00
Retained Earnings	-8.7%	-397	-365	-332	-297	-262	-230	-199	-172	-145	-122	-98.60	-78.76	-48.08
Additional Paid-In Capital	1.0%	553	548	519	513	508	504	493	477	474	472	470	437	0.00
Shares Outstanding	0.1%	50.00	50.00	50.00	50.00	49.00	49.00	47.00	47.00	47.00	47.00	18.00	5.00	2.00
Float	-	-	-	-	234	-	-	-	303	-	-	-	655	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-228.8%	-38,165	29,634	-24,706	-25,324	-23,406	-23,961	-20,600	-20,501	-27,404	-14,172	-17,794	-13,582	-13,815	-	-	-
Share Based Compensation	19.6%	4,873	4,074	4,468	4,153	3,974	3,326	3,214	2,873	2,251	1,856	2,073	1,019	252	-	-	-
Cashflow From Investing	-31.1%	9,853	14,297	35,628	18,550	20,326	-53,939	29,489	-14,249	-180,520	-3,047	-1,688	-2,701	-2,217	-	-	-
Cashflow From Financing	-99.0%	246	25,173	1,101	1,200	18.00	20,434	-217	96.00	153	-135	29,456	205,472	142,769	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GLUE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration Revenue	$ 1,064	$ 0
Operating expenses:
Research and development	27,026	26,755
General and administrative	8,985	7,504
Total operating expenses	36,011	34,259
Loss from operations	(34,947)	(34,259)
Other income (expense):
Interest income	2,442	2,437
Foreign currency exchange gain (loss), net	620	(85)
Loss on sale of marketable securities	0	(131)
Total other income	3,062	2,221
Net loss before income taxes	(31,885)	(32,038)
Provision for income taxes	(83)	0
Net loss	$ (31,968)	$ (32,038)
Net loss per share-basic	$ (0.53)	$ (0.65)
Net loss per share-diluted	$ (0.53)	$ (0.65)
Weighted-average number of shares outstanding used in computing net loss per common share-basic	60,156,187	49,347,473
Weighted-average number of shares outstanding used in computing net loss per common share-diluted	60,156,187	49,347,473
Other comprehensive income (loss):
Provision for pension benefit obligation	$ 35	$ 14
Unrealized gain (loss) on available-for-sale securities	(4)	345
Comprehensive loss	$ (31,937)	$ (31,679)

GLUE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 99,752	$ 128,101
Marketable securities	93,140	104,312
Other receivables	601	505
Prepaid expenses and other current assets	5,543	3,294
Total current assets	199,036	236,212
Property and equipment, net	34,036	33,803
Operating lease right-of-use assets	28,422	28,808
Restricted cash	4,863	4,580
Other long-term assets	389	352
Total assets	266,746	303,755
Current liabilities:
Accounts payable	6,828	11,152
Total other current liabilities	10,713	14,600
Current deferred revenue	20,407	17,678
Current portion of operating lease liability	3,345	3,162
Total current liabilities	41,293	46,592
Deferred revenue, net of current	28,529	32,323
Defined benefit plan liability	2,568	2,713
Operating lease liability	41,837	42,877
Total liabilities	114,227	124,505
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized, 50,210,309 shares issued and 50,200,304 shares outstanding as of March 31, 2024; and 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023	5	5
Additional paid-in capital	553,063	547,857
Accumulated other comprehensive loss	(2,693)	(2,724)
Accumulated deficit	(397,856)	(365,888)
Total stockholders' equity	152,519	179,250
Total liabilities and stockholders' equity	$ 266,746	$ 303,755

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

CEO	Dr. Markus Warmuth M.D.
WEBSITE	monterosatx.com
INDUSTRY	Biotechnology
EMPLOYEES	133

Monte Rosa Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Monte Rosa Therapeutics, Inc.? What does GLUE stand for in stocks?

GLUE is the stock ticker symbol of Monte Rosa Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Monte Rosa Therapeutics, Inc. (GLUE)?

As of Fri May 17 2024, market cap of Monte Rosa Therapeutics, Inc. is 261.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLUE stock?

You can check GLUE's fair value in chart for subscribers.

What is the fair value of GLUE stock?

You can check GLUE's fair value in chart for subscribers. The fair value of Monte Rosa Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Monte Rosa Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GLUE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Monte Rosa Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GLUE is over valued or under valued. Whether Monte Rosa Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Monte Rosa Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLUE.